Vutiglabridin Modulates Paraoxonase 1 and Ameliorates Diet-Induced Obesity in Hyperlipidemic Mice

Vutiglabridin is a clinical-stage synthetic small molecule that is being developed for the treatment of obesity and its target proteins have not been fully identified. Paraoxonase-1 (PON1) is an HDL-associated plasma enzyme that hydrolyzes diverse substrates including oxidized low-density lipoprotei...

Descripción completa

Detalles Bibliográficos
Autores principales: Sulaiman, Dawoud, Choi, Leo Sungwong, Lee, Hyeong Min, Shin, Jaejin, Kim, Dong Hwan, Lee, Keun Woo, Eftekhari, Pierre, Quartier, Angélique, Park, Hyung Soon, Reddy, Srinivasa T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10135725/
https://www.ncbi.nlm.nih.gov/pubmed/37189434
http://dx.doi.org/10.3390/biom13040687

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10135725/
https://www.ncbi.nlm.nih.gov/pubmed/37189434
http://dx.doi.org/10.3390/biom13040687

Ejemplares similares